Down Syndrome and COVID-19: A Perfect Storm?
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
People with Down syndrome show signs of chronic immune dysregulation, including a higher prevalence of autoimmune disorders, increased rates of hospitalization during respiratory viral infections, and higher mortality rates from pneumonia and sepsis. At the molecular and cellular levels, they show markers of chronic autoinflammation, including interferon hyperactivity, elevated levels of many inflammatory cytokines and chemokines, and changes in diverse immune cell types reminiscent of inflammatory conditions observed in the general population. However, the impact of this immune dysregulation in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and CoV disease of 2019 (COVID-19) remains unknown. This Perspective outlines why individuals with Down syndrome should be considered an at-risk population for severe COVID-19. Specifically, the immune dysregulation caused by trisomy 21 may result in an exacerbated cytokine release syndrome relative to that observed in the euploid population, thus justifying additional monitoring and specialized care for this vulnerable population.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ruan, Q., Yang, K., Wang, W., Jiang, L., & Song, J. (2020) · Intensive Care Medicine · doi:10.1007/s00134-020-05991-x · Cited by 4,898
Into the Eye of the Cytokine Storm
Tisoncik, J. R., Korth, M. J., Simmons, C. P., Farrar, J., Martin, T. R., & Katze, M. G. (2012) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.05015-11 · Cited by 1,940 · cited 2×
“Cytokine storms, also known as cytokine release syndrome (CRS) or hypercytokinemia, have been described as drivers of pathology in myriad infectious and non-infectious diseases.(36) Among infectious diseases, cytokine storms have been postulated to drive mortality during severe viral infections, such as influenza,(37)…”
Morens, D. M., Taubenberger, J. K., & Fauci, A. S. (2008) · The Journal of Infectious Diseases · doi:10.1086/591708 · Cited by 1,625 · cited 1×
“During later influenza pandemics in the 1950s and 1960s, the percentage of deaths due to bacterial lung infections was estimated at 50%–70%, with the decreases being explained by the broader use of antibiotics.(66,67) In the COVID-19 pandemic, the impact of secondary bacterial infections is likely to be further decrea…”
BackgroundAn interferon‐γ‐related cytokine storm in SARS patients
Huang, K., Su, I., Theron, M., Wu, Y., Lai, S., Liu, C., & Lei, H. (2005) · Journal of Medical Virology · doi:10.1002/jmv.20255 · Cited by 679
The 1918 Influenza Pandemic: Insights for the 21st Century
Morens, D. M., & Fauci, A. S. (2007) · The Journal of Infectious Diseases · doi:10.1086/511989 · Cited by 536
T cell-mediated immune response to respiratory coronaviruses
Channappanavar, R., Zhao, J., & Perlman, S. (2014) · Immunologic Research · doi:10.1007/s12026-014-8534-z · Cited by 512 · cited 2×
“During respiratory viral infections, as viral particles enter the lung tissue, lung-resident respiratory dendritic cells (rDCs) acquire antigens from the epithelial cells or are infected themselves, thus being activated and draining to mediastinal and cervical lymph nodes, where they process viral antigens and present…”
BackgroundType I IFNs mediate development of postinfluenza bacterial pneumonia in mice
Shahangian, A., Chow, E. K., Tian, X., Kang, J. R., Ghaffari, A., Liu, S. Y., Belperio, J. A., Cheng, G., & Deng, J. C. (2009) · Journal of Clinical Investigation · doi:10.1172/jci35412 · Cited by 479
Infections and immunodeficiency in Down syndrome
Ram, G., & Chinen, J. (2011) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2011.04335.x · Cited by 465 · cited 12×
“In a mouse model of influenza A, treatment with anti-IL-10 neutralizing antibodies before inoculation with S. pneumoniae resulted in reduced bacterial outgrowth and reduced lethality during secondary bacterial pneumonia.70 In the case of tuberculosis, type I IFN signaling was shown to actually promote Mycobacterium tu…”
BackgroundInfluentialMeta-analysis of the association between obstructive sleep apnoea and postoperative outcome
Kaw, R., Chung, F., Pasupuleti, V., Mehta, J., Gay, P. C., & Hernandez, A. V. (2012) · British Journal of Anaesthesia · doi:10.1093/bja/aes308 · Cited by 449
Trisomy 21 consistently activates the interferon response
Sullivan, K. D., Lewis, H. C., Hill, A. A., Pandey, A., Jackson, L. P., Cabral, J. M., Smith, K. P., Liggett, L. A., Gomez, E. B., Galbraith, M. D., et al. (2016) · eLife · doi:10.7554/elife.16220 · Cited by 362
Self-citation
Cited by
The establishment of reference sequence for SARS‐CoV‐2 and variation analysis
Wang, C., Liu, Z., Chen, Z., Huang, X., Xu, M., He, T., & Zhang, Z. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25762 · Cited by 494
Interleukin-6 in Rheumatoid Arthritis
Pandolfi, F., Franza, L., Carusi, V., Altamura, S., Andriollo, G., & Nucera, E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155238 · Cited by 278
Araya, P., Waugh, K. A., Sullivan, K. D., Núñez, N. G., Roselli, E., Smith, K. P., Granrath, R. E., Rachubinski, A. L., Enriquez Estrada, B., Butcher, E. T., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1908129116 · Cited by 179
Self-citationGalbraith, M. D., Rachubinski, A. L., Smith, K. P., Araya, P., Waugh, K. A., Enriquez-Estrada, B., Worek, K., Granrath, R. E., Kinning, K. T., Paul Eduthan, N., et al. (2023) · Science Advances · doi:10.1126/sciadv.adg6218 · Cited by 88
“Individuals with DS are at high risk of severe complications and mortality from SARS-CoV-2 infections ( 6 , 62 ) and stand to benefit from JAK inhibitors and other anti-inflammatory agents approved for severe COVID-19 ( 63 ).”
Self-citationJAK1 Inhibition Blocks Lethal Immune Hypersensitivity in a Mouse Model of Down Syndrome
Tuttle, K. D., Waugh, K. A., Araya, P., Minter, R., Orlicky, D. J., Ludwig, M., Andrysik, Z., Burchill, M. A., Tamburini, B. A. J., Sempeck, C., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108407 · Cited by 72
“, 2010) infection, people with DS are likely to develop more severe complications upon SARS-CoV-2 infection, including higher rates of hospitalization, mortality, and secondary bacterial infection (De Cauwer and Spaepen, 2020; Espinosa, 2020; Villani et al., 2020).”
BackgroundSelf-citation
Metadata
- Authors
- Espinosa, J. M.
- Venue
- Cell Reports Medicine
- Publisher
- Elsevier BV
- Published
- 2020-05
- Volume
- 1
- Issue
- 2
- Pages
- 100019
- ISSN
- 2666-3791 (ISSN-L)
- OpenAlex
- W3023856581
- Cited by
- 128
- References
- 21
- FWCI
- 2.84
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Down Syndrome and COVID-19: A Perfect Storm? https://app.cochat.ai/papers/10.1016/j.xcrm.2020.100019
- The paper
- Espinosa, J. M. (2020). Down Syndrome and COVID-19: A Perfect Storm? Cell Reports Medicine. https://doi.org/10.1016/j.xcrm.2020.100019
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.